Differential gene expression profile of retinoblastoma compared to normal retina

Molecular Vision

Volumn 16, Issue , 2010, Pages 1292-1303

  Ganguly, Arupa ^a   Shields, Carol L ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ATR PROTEIN; AUTOTAXIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL MARKER; CHECKPOINT KINASE 1; POLO LIKE KINASE; RETINOBLASTOMA 1 PROTEIN; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC RECOMBINATION; HUMAN; HUMAN TISSUE; INFANT; MALE; MICROARRAY ANALYSIS; MITOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PURINE METABOLISM; RETINA CONE; RETINOBLASTOMA;

CHILD, PRESCHOOL; CONSENSUS SEQUENCE; DNA MUTATIONAL ANALYSIS; E2F TRANSCRIPTION FACTORS; EXONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFANT; MALE; PROTEIN BINDING; RETINA; RETINOBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955610458     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009; 93:21-3.
2. Fletcher O, Easton D, Anderson K, Gilham C, Jay M. J P. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004; 96:357-63.
3. Lee TC, Hayashi NI, Dunkel IJ, Beaverson K, Novetsky D, Abramson DH. New retinoblastoma tumor formation in children initially treated with systemic carboplatin. Ophthalmology 2003; 110:1989-94.
4. Stevens KR Jr. Second primary tumors in hereditary retinoblastoma. Ophthalmology 2002; 109:1947.
5. Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M, Fraumeni JF Jr, Kleinerman RA. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009; 101:581-91.
6. Meadows AT, Leahey AM. More about second cancers after retinoblastoma. J Natl Cancer Inst 2008; 100:1743-5.
7. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008; 100:1771-9.
8. MacCarthy A, Bayne AM, Draper GJ, Eatock EM, Kroll ME, Stiller CA, Vincent TJ, Hawkins MM, Jenkinson HC, Kingston JE, Neale R, Murphy MF. Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004. Br J Ophthalmol 2009; 93:1159-62.
9. Hagstrom SA, Dryja TP. Mitotic recombination map of 13cen-13q14 derived from an investigation of loss of heterozygosity in retinoblastoma. Proc Natl Acad Sci USA 1999; 96:2952-7.
10. Ganguly A, Nichols KE, Grant G, Rappaport E, Shields C. Molecular karyotype of sporadic unilateral retinoblastoma tumors. Retina 2009; 29:1002-12.
11. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8:671-82.
12. Gratias S, Schüler A, Hitpass LK, Stephan H, Rieder H, Schneider S, Horsthemke B, Lohmann DR. Genomic gains on chromosome 1q in retinoblastoma: consequences on gene expression and association with clinical manifestation. Int J Cancer 2005; 116:555-63.
13. Chakraborty S, Khare S, Dorairaj SK, Prabhakaran VC, Prakash DR, Kumar A. Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics 2007; 90:344-53.
14. Zheng L, Lee WH. Retinoblastoma tumor suppressor and genome stability. Adv Cancer Res 2002; 85:13-50.
15. Shields JA, Shields CL, Lally SE, Eagle RC Jr. Harvesting fresh tumor tissue from enucleated eyes: the 2008 Jack S. Guyton lecture. Arch Ophthalmol 2010; 128:241-3.
16. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4:249-64.
17. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98:5116-21.
18. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, Shields JA. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113:2276-80.
19. Lambert S. Postnatal Growth of the Eye and Emmetropization. Second Edition ed. Victoria, Australia: Blackwell Sciences Ltd; 1997.
20. Xu XL, Fang Y, Lee TC, Forrest D, Gregory-Evans C, Almeida D, Liu A, Jhanwar SC, Abramson DH, Cobrinik D. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 2009; 137:1018-31.
21. Vernell R, Helin K, Muller H. Identification of target genes of the p16INK4A-pRB-E2F pathway. J Biol Chem 2003; 278:46124-37.
22. Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H, Ikeda Y, Kizaki M. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 2007; 31:285-91.
23. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68:820-3.
24. Lee EY, Lee WH. Molecular cloning of the human esterase D gene, a genetic marker of retinoblastoma. Proc Natl Acad Sci USA 1986; 83:6337-41.
25. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987; 235:1394-9.
26. Rabinovich A, Jin VX, Rabinovich R, Xu X. PJ. F. E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites. Genome Res 2008; 18:1763-77.
27. Semizarov D, Kroeger P, Fesik S. siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res 2004; 32:3836-45.
28. Chakraborty S, Khare S, Dorairaj SK, Prabhakaran VC, Prakash DR, Kumar A. Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics 2007; 90:344-53.
29. Ajioka I, Martins RA, Bayazitov IT, Donovan S, Johnson DA, Frase S, Cicero SA, Boyd K, Zakharenko SS, Dyer MA. Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice. Cell 2007; 131:378-90.
30. MacPherson D, Dyer MA. Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. Cancer Res 2007; 67:7547-50.
31. Lee TC, Almeida D, Claros N, Abramson DH, Cobrinik D. Cell cycle-specific and cell type-specific expression of Rb in the developing human retina. Invest Ophthalmol Vis Sci 2006; 47:5590-8.
32. Ge NL, Elferink CJ. A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle. J Biol Chem 1998; 273:22708-13.
33. Ikuta T, Eguchi H, Tachibana T, Yoneda Y, Kawajiri K. Nuclear localization and export signals of the human aryl hydrocarbon receptor. J Biol Chem 1998; 273:2895-904.
34. Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, Schwarz M, Weller M, Tritschler I. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene 2009; 28:2593-605.
35. Weber G. Enzymes of purine metabolism in cancer. Clin Biochem 1983; 16:57-63.
36. Zaza G, Yang W, Kager L, Cheok M, Downing J, Pui CH, Cheng C, Relling MV, Evans WE. Acute lympnoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood 2004; 104:1435-41.
37. Gunawardena RW, Siddiqui H, Solomon DA, Mayhew CN, Held J, Angus SP, Knudsen ES. Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1. J Biol Chem 2004; 279:29278-85.
38. Eckerdt F, Strebhardt K. Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 2006; 66:6895-8.
39. Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, Matsunaga T, Hiyama E, Hayashi Y, Ando H, Suita S, Kaneko M, Sasaki F, Hashizume K, Ohnuma N, Nakagawara A. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004; 23:5901-11.
40. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30.
41. Longworth MS, Herr A, Ji JY, Dyson NJ. RBF1 promotes chromatin condensation through a conserved interaction with the Condensin II protein dCAP-D3. Genes Dev 2008; 22:1011-24.
42. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006; 6:99-106.